This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Learn more here.

VNRX Insider Trading

Insider Ownership Percentage: 15.40%
Insider Buying (Last 12 Months): $137,836.48
Insider Selling (Last 12 Months): $33,000.00

VolitionRx Insider Trading History Chart

This chart shows the insider buying and selling history at VolitionRx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

VolitionRx Share Price & Price History

Current Price: $0.98
Price Change: Price Decrease of -0.03 (-2.96%)
As of 02/29/2024 01:00 AM ET

This chart shows the closing price history over time for VNRX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Learn more here.

VolitionRx Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/2/2024Corp Ltd EightMajor ShareholderSell20,000$0.90$18,000.00298,419View SEC Filing Icon  
12/18/2023Salvatore Thomas ButeraCEOBuy10,000$0.83$8,300.0099,350View SEC Filing Icon  
12/15/2023Corp Ltd EightMajor ShareholderSell20,000$0.75$15,000.00318,419View SEC Filing Icon  
12/15/2023Salvatore Thomas ButeraCEOBuy10,000$0.77$7,700.0089,350View SEC Filing Icon  
12/13/2023Rodney Gerard RootsaertInsiderBuy10,000$0.60$6,000.0078,652View SEC Filing Icon  
12/8/2023Cameron John ReynoldsCEOBuy10,000$0.67$6,700.001,704,518View SEC Filing Icon  
11/27/2023Guy Archibald InnesDirectorBuy20,000$0.77$15,400.00627,161View SEC Filing Icon  
11/24/2023Guy Archibald InnesDirectorBuy10,000$0.76$7,600.00607,161View SEC Filing Icon  
11/22/2023Guy Archibald InnesDirectorBuy20,000$0.71$14,200.00597,161View SEC Filing Icon  
11/16/2023Salvatore Thomas ButeraCEOBuy10,000$0.81$8,100.0079,350View SEC Filing Icon  
9/5/2023Phillip BarnesDirectorBuy5,000$1.30$6,500.0024,686View SEC Filing Icon  
8/31/2023Martin Charles FaulkesDirectorBuy9,716$1.28$12,436.481,673,532View SEC Filing Icon  
8/29/2023Jacob Vincent MicallefInsiderBuy11,250$1.24$13,950.0046,250View SEC Filing Icon  
8/25/2023Jacob Vincent MicallefInsiderBuy20,000$1.24$24,800.00235,140View SEC Filing Icon  
8/24/2023Gaetan MichelCOOBuy5,000$1.23$6,150.00212,997View SEC Filing Icon  
See Full Table
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Learn more here.

SEC Filings (Institutional Ownership Changes) for VolitionRx (NYSE:VNRX)

8.26% of VolitionRx stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at VNRX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

VolitionRx Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/15/2024Vanguard Group Inc.629,639$0.45M0.0%+16.1%0.800%Search for SEC Filing on Google Icon
1/17/2024Silverberg Bernstein Capital Management LLC147,038$0.11M0.1%N/A0.187%Search for SEC Filing on Google Icon
12/18/2023Vanguard Group Inc.542,444$0.37M0.0%+4.2%0.689%Search for SEC Filing on Google Icon
11/14/2023Lagoda Investment Management L.P.3,882,850$2.68M1.8%-1.2%4.969%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
VolitionRx logo
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 worldwide. It offers Nu.Q Vet cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer that detect cancer; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company is based in Henderson, Nevada.
Read More on VolitionRx

Today's Range

Now: $0.98
Low: $0.98
High: $1.02

50 Day Range

MA: $0.97
Low: $0.65
High: $1.19

52 Week Range

Now: $0.98
Low: $0.55
High: $2.10

Volume

22,047 shs

Average Volume

209,952 shs

Market Capitalization

$77.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42

Who are the company insiders with the largest holdings of VolitionRx?

VolitionRx's top insider investors include:
  1. Cameron John Reynolds (CEO)
  2. Martin Charles Faulkes (Director)
  3. Guy Archibald Innes (Director)
  4. Corp Ltd Eight (Major Shareholder)
  5. Jacob Vincent Micallef (Insider)
  6. Gaetan Michel (COO)
  7. Salvatore Thomas Butera (CEO)
  8. Rodney Gerard Rootsaert (Insider)
  9. Phillip Barnes (Director)
Learn More about top insider investors at VolitionRx.

Who are the major institutional investors of VolitionRx?

VolitionRx's top institutional investors include:
  1. Vanguard Group Inc. — 0.80%
  2. Silverberg Bernstein Capital Management LLC — 0.19%
  3. Concourse Financial Group Securities Inc. — 0.00%
Learn More about top institutional investors of VolitionRx stock.

Which institutional investors are buying VolitionRx stock?

During the last quarter, VNRX stock was acquired by institutional investors including:
  1. Silverberg Bernstein Capital Management LLC
  2. Vanguard Group Inc.
Within the previous year, these company insiders have bought VolitionRx stock:
  1. Cameron John Reynolds (CEO)
  2. Martin Charles Faulkes (Director)
  3. Guy Archibald Innes (Director)
  4. Corp Ltd Eight (Major Shareholder)
  5. Jacob Vincent Micallef (Insider)
  6. Gaetan Michel (COO)
  7. Salvatore Thomas Butera (CEO)
  8. Rodney Gerard Rootsaert (Insider)
Learn More investors buying VolitionRx stock.
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Full details and steps to take here.